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Renal cell carcinoma accounts for only 2% of all cancers but its
incidence is increasing (Ries et al, 1997). Radical nephrectomy is
potentially curative for those with local disease. However, approxi-
mately 25% of patients present with metastatic disease and a
further 30–40% of patients with disease that is apparently confined
to the kidney at presentation will eventually develop systemic
spread (Rabinovitch et al, 1994). The prognosis for patients with
metastases is very poor and median survival is only 6 months (Selli
et al, 1983). Renal cell carcinoma is not chemosensitive, although
short-duration responses can be obtained with vinblastine (response
rate 7%) and 5-fluorouracil (response rate 10%) (Yagoda et al,
1995). The mainstay of treatment for metastatic renal cell carci-
noma is immunotherapy with alpha-interferon (IFN-α ) or inter-
leukin-2 (IL-2), both of which have demonstrated response rates of
10–30% (Muss, 1991; Bukowski, 1997). Recently, a randomized
MRC trial showed a significant survival advantage for interferon
compared to medroxyprogesterone: median survival 8.5 vs 6
months and response rate 14% vs 2% (Medical Research Council
Renal Cancer Collaborators, 1999). Some reports have suggested
that IL-2 results in slightly higher response rates of 15–30%
(Rosenberg et al, 1994; Fyfe et al, 1995) compared with 10–20%
for IFN-α (Muss, 1991; Minasian et al, 1993) and longer median
survival 16 months (Fyfe et al, 1995) vs 11 months (Minasian et al,
1993)) and that more patients achieve durable complete remissions.
However, a randomized study has failed to show any difference in
efficacy between these two cytokines (Negrier et al, 1998). In this
trial a third arm involved a combination of IFN-α and IL-2 and
although higher response rates and longer event-free survival were
reported with the combination, there was no overall survival
benefit. Thus, current standard therapy for patients with metastatic
renal cell carcinoma is either single-agent IFN-α or IL-2 in those fit
enough to tolerate the treatment.
The highest response rates in metastatic renal cell cancer have
been reported with a combination of IFN-α –IL-2–5FU (bolus)
given according to the regimen first described by Atzpodien and
colleagues (Atzpodien et al, 1993; 1997; Hofmockel et al, 1996;
Ellerhorst et al, 1997). However, the optimal method of delivery of
these drugs remains to be established. In a previous study at 
the Royal Marsden Hospital, we demonstrated the feasibility of
combining PVI (protracted venous infusion) 5FU with subcuta-
neous IL-2 in patients with metastatic renal cell cancer (Savage et
al, 1997) and we now report our experience of adding IFN-α 2a to
this regimen at the same dose and schedule of IFN-α and IL-2 as
that described by Aztpodien et al (1993).
PATIENTS AND METHODS
Patients
Patients were eligible for the study if they had histologically
proven renal cell carcinoma with metastatic disease. Inclusion
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Summary Our purpose was to assess the activity of alpha-interferon (IFN-α ), interleukin-2 (IL-2) and 5 fluorouracil (5FU) administered by
protracted venous infusion (PVI) as opposed to bolus injection. 55 patients with advanced renal cell cancer were treated as follows: IL-2 and
IFN-α according to the schedule originally described by Atzpodien, with PVI 5FU 200 mg m–2 day–1 during weeks 5–9. 42 patients (76%) were
of moderate or poor prognosis as defined by previous studies. The response rate by intention to treat was 31% (17 of 55, three complete
response, 14 partial response; 95% CI = 19–45%) and in evaluable patients (completed one cycle, n = 42), it was 40% (95% CI = 26–57%).
In addition, 24% (13 of 55) patients achieved disease stabilization. The overall median survival was 11 months with a 1-year survival of 45%.
The median survival for evaluable patients was 18 months with 1- and 2-year survivals of 60% and 40% respectively. The median survival of
responding patients was 31 months and the three patients achieving complete response remain progression-free at 14+, 18+ and 23+
months. Evaluable patients with poor prognostic features achieved a response rate of 54% and median survival of 18 months. Toxicity was
significant yet manageable with 12 patients unable to complete one cycle due to side-effects and 36% experiencing grade 3–4 toxicities. The
three on-treatment deaths were considered unlikely to be due to toxicity. The schedule of IFN-α , IL-2 and PVI 5FU has significant activity in
advanced renal cell cancer with manageable toxicity. It is of particular interest that this regimen appears to have high activity in fit patients with
poor prognostic features. © 2000 Cancer Research Campaign
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doi: 10.1054/ bjoc.2000.1418, available online at http://www.idealibrary.com on criteria were as follows: age > 18 years; Eastern Co-operative
Oncology Group (ECOG) performance status (PS) 0–2; bidimen-
sionally measurable disease; normal haematological and biochem-
ical parameters and a glomerular filtration rate greater than 
60 ml min–1. Patients were excluded if they had any significant
other medical illness, previous or concomitant malignancy
(excluding cervical carcinoma in situ or basal cell carcinoma of
skin), cerebral metastases, or had received chemotherapy, radio-
therapy or immunotherapy within the previous 4 weeks. Patients
who had received prior biochemotherapy, or who were taking long-
term corticosteroids, were excluded. Written informed consent was
obtained from all patients in accordance with the Royal Marsden
Hospital Research and Ethics Committee guidelines.
Prognostic factors identified in earlier studies (Elson et al, 1988;
Palmer et al, 1992; Jones et al, 1993; Fossa et al, 1995) were used
to categorize patients into three groups. These factors were: 
PS > 0; more than one metastatic site; interval from diagnosis of
primary tumour to treatment of metastatic disease < 2 years.
Patients with 0 or 1 factors were defined as good prognosis,
patients with 2 factors as moderate prognosis, and patients with 3
factors as poor prognosis.
Pre-treatment evaluation
Pre-treatment assessment included full and differential blood count,
electrolytes, calcium, liver enzymes, thyroid function tests and coag-
ulation profile. Baseline electrocardiograms and chest radiographs
were also performed. Tumour assessment was by computed tomog-
raphy (CT) scan and/or plain X-rays as appropriate.
Treatment
A 9-week treatment schedule was employed as in Table 1. Patients
were admitted for treatment during weeks 1 and 4. A Hickman line
was inserted during week 4 and warfarin was commenced at a dose
of 1 mg daily as prophylaxis against Hickman line-associated
thrombosis. Patients who received a second or third cycle of treat-
ment continued their PVI 5FU throughout the entire 9 weeks of
these cycles.
Toxicity assessment
Patients were evaluated for toxicity at weeks 1, 4 and 9. Treatment
toxicity was assessed using National Cancer Institute of Canada
Clinical Trials Group (NCIC-CTG) Expanded Common Toxicity
Criteria (CTC). Paracetamol and/or naproxen were used to 
ameliorate the constitutional side-effects of IFN-α and IL-2.
Chlorpheniramine was used to relieve pruritus when it occurred
and anti-emetics, sedatives and anti-diarrhoeal agents were given
as necessary. Intravenous colloids were used for the initial treat-
ment of IL-2-induced hypotension, followed by dopamine if
required. Dose modifications for 5FU toxicity were made as
follows: mucositis or palmar-plantar erythema (≥ grade 2) or 
diarrhoea (≥ grade 3), 5FU stopped until resolution of toxicity 
and restarted with a 25% dose reduction.
Assessment of response
Tumour response was assessed radiologically at week 9 of each
cycle. Complete response (CR) was defined as the disappearance
of all known disease, partial response (PR) as a 50% or more
decrease in the sum of the products of largest and perpendicular
diameters of measurable lesions without the appearance of new
lesions or progression of any existing lesion, progressive disease
(PD) as a 25% or more increase in size of one or more measurable
lesions, or the appearance of a new lesion(s) and stable disease
(SD) as a < 25% increase or < 50% decrease in the size of measur-
able lesions without the appearance of new lesions or progression
of any existing lesion. Patients who demonstrated CR, PR or SD
proceeded to a second cycle of treatment. Patients were subse-
quently followed up at 3-monthly intervals.
Statistical analysis
Lifetable curves and median survivals were calculated using the
Kaplan–Meier method. Fisher’s exact test and the Mann–Whitney
test for trend were used to compare proportions.
RESULTS
Patient characteristics
The characteristics of the 55 patients who entered the study are
shown in Table 2. Forty-seven patients (85%) had more than one
disease site at the time of treatment initiation; 26 patients (47%)
had an ECOG PS of 1 and two patients (4%) had a PS of 2. The
time from diagnosis to treatment of metastatic disease was < 2
years in 41 patients (74.5%). Table 3 shows the distribution of
patients according to prognostic group: 13 patients (23.5%) had a
good prognosis, 23 patients (42%) had a moderate prognosis and
19 patients (34.5%) were in the poor prognosis group. Thus, 42
patients (76.5%) were in a moderate or poor prognosis group.
Toxicities
All patients were evaluable for toxicity and Table 4 shows these
toxicities according to NCIC-CTG CTC grade (worst toxicity per
patient). All patients experienced at least one episode of grade 1 or
2 toxicity. Seventeen patients experienced one or more non-
haematological grade 3 toxicity, and grade 4 toxicity was seen in
three patients (one patient grade 4 dyspnoea, one patient grade 4
infection and one patient vomiting and hypotension both grade 4).
Patients were electively admitted to hospital during weeks 1 and
4, as this was the time when higher doses of IL-2 were adminis-
tered. As a result, toxicities during this period were closely moni-
tored. Twelve patients (22%) failed to complete the first course of
treatment because of unacceptable toxicity: six of these were in the
poor prognosis group, three in the moderate prognosis group and
three in the good prognosis group.
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Table 1 Treatment schedule
Weeks 1 and 4 Day 1 sc IFN-α 2a 6 MU m–2
Days 3–5 sc IL-2 10 MU m–2 bd
Weeks 2 and 3 Days 1, 3, 5 sc IFN-α 2a 6 MU m–2
sc IL-2 5 MU m–2
Weeks 5–8 PVI 5FU 200 mg m–2 day–1
Days 1, 3, 5 sc IFN-α 2a 9 MU m–2
Week 9 Response assessment
PVI 5FU continued
Option of further cycle in responding patients,
commencing week 10Three patients died while on treatment. One patient died 
of a haemorrhagic cerebrovascular accident during week 9 of her
second cycle of treatment. She had been anticoagulated with
warfarin following a diagnosis of pulmonary embolism 4 months
prior to starting treatment. The second patient died during his third
cycle of treatment from previously undiagnosed progressive cere-
bral metastases associated with oedema which caused tentorial
herniation. Post-mortem examination was not undertaken in accor-
dance with the wishes of the next-of-kin. The third patient was
admitted to her local hospital with a history of sudden-onset dysp-
noea during week 9 of the first cycle of treatment, before any
response assessment had been carried out. She died on the day of
admission and although no post-mortem was performed, the clin-
ical diagnosis was pulmonary embolism.
Response to treatment and survival
Response to treatment was analysed by intention to treat and the
overall response rate was 31% (17 of 55; 95% CI = 19–45%) with
a complete response rate of 5.4% (3 of 55; 95% CI = 1.1–15%) and
a partial response rate of 25% (14 of 55; 95% CI = 15–39%).
Stabilization of disease was seen in a further 13 patients (23.6%).
The response rate was 15% in the good prognosis group, 35% in
the moderate prognosis group, and 37% in the poor prognosis
group. Overall median progression-free survival was 20 weeks
(range 1–98+) and median duration of response was 73 weeks
(range 6–88+). The median survival by intention to treat was 47
weeks (range 2–134) with no significant differences between
prognostic groups. The 1-year survival was 45% overall; interest-
ingly 33% for the good prognosis group and 45% for poor prog-
nosis patients.
An analysis of evaluable patients (Table 5) was also undertaken.
This excluded patients in whom response could not be assessed,
i.e. those who failed to complete one cycle of treatment because of
unacceptable toxicity and the patient who died during the first
cycle. There were 42 evaluable patients and the response rate in
this group was 40% (17 of 42; 95% CI = 26–57%). Their median
survival was 79 weeks (range 12–134), 1-year survival 60% and 
2-year survival 40%. The median survival of responding patients
was 30.9 months (range 4.1–30.9), and the three patients who
achieved CR remain progression-free at their last follow up at 14+,
18+ and 23+ months respectively. Their clinical features are
shown in Table 6.
We did not find that response was associated with good
prognosis group (Table 5). On the contrary, there was a trend
towards a higher response rate and longer survival in the 
poor prognosis group, although this did not reach statistical
significance.
DISCUSSION
The optimal treatment regimen for patients with metastatic renal
cell cancer remains to be established. The highest response rates
have been reported for a combination of IFN-α –IL-2–5FU (bolus).
The combination of subcutaneous IFN-α –IL-2 with PVI 5FU 
as reported here utilizes the same doses and schedule of IFN-α
and IL-2 as that described by Atzpodien and colleagues for the
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Table 2 Patient characteristics
Characteristics n
Sex
Male 44
Female 11
Age, years
Median 52
Range 28–66
Prior nephrectomy 49
Prior treatment 7
IL-12 3
IFN 3
Radiotherapy 1
ECOG performance status
02 7
12 6
22
No. of disease sites
18
22 7
31 2
46
52
Time from diagnosis to treatment of
metastatic disease
0–12 mths 30
12–24 mths 11
>24 mths 14
Sites of metastases
Lung 39
Bone 12
Lymph nodes 29
Liver 7
Renal bed 21
Table 3 Prognostic groups
Prognostic group Poor prognostic
factorsa (n) Patients (n)
Good 0 or 1 13
Moderate 2 23
Poor 3 19
aPrognostic factors = PS > 0; > 1 site of disease; < 2 years from primary
diagnosis to treatment of metastatic disease
Table 4 Toxicity
CTC Grade (worst per patient)
0123 4
Cytokine-related
Malaise 6 20 24 5 0
Rigors 17 31 7 0 0
Skin flushing 9 29 15 2 0
Hypotension 30 6 15 3 1
Oedema 36 13 6 0 0
Dyspnoea 43 4 4 3 1
Vomiting 26 12 14 2 1
Nausea 17 14 18 6 0
Myalgia 23 24 8 0 0
5-FU-related
Stomatitis 40 6 7 2 0
Diarrhoea 32 11 12 0 0
Haematological
Anaemia 19 1 33 2 0
Leucopenia 36 12 7 0 0
Thrombocytopenia 51 0 1 3 0
Neutropenia 32 6 10 7 0
Infection 46 5 2 1 1IFN-α –IL-2–5FU (bolus) combination. We have shown that IFN-
α –IL-2–PVI 5FU is feasible and results in high response rates that
are comparable with those seen in some other studies of this com-
bination (Atzpodien et al, 1993; 1997; Hofmockel et al, 1996; El-
lerhorst et al, 1997). These encouraging results are of particular
interest because of the relatively poor prognostic features of our
patients.
The reported response rates to IFN-α –IL-2–5FU (bolus) vary
widely from 1.8–48.6% (Atzpodien et al, 1993; 1997; Dutcher et
al, 1996; Hofmockel et al, 1996; Ellerhorst et al, 1997; Negrier et
al, 1997; Ravaud et al, 1998; Tourani et al, 1998) (Table 7) and two
main factors probably account for this. First, the patient character-
istics of the study populations and secondly, differences in the
scheduling of the drugs. For instance, Ravaud and colleagues
reported that a combination of interferon, IL-2 and 5FU was 
inactive with a response rate of only 1.8% (Ravaud et al, 1998).
The scheduling and dosing of the agents in this study was very
different to the regimen as originally described by Atzpodien and
colleagues with IFN-α and IL-2 total doses of 72 MU m–2 and 216
MU m–2 respectively, as opposed to 156 MU m–2 and 150 MU m–2.
Furthermore, in the Ravaud study IL-2 was given subcutaneously
for 6 days every other week for 8 weeks, whereas it was given on
days 3, 4 and 5 of weeks 1 and 4 and days 1, 3 and 5 of weeks 2
and 3 in the Aztpodien regimen. IFN-α is administered on day 1 of
weeks 1 and 4, and days 1, 3 and 5 of weeks 2 and 3 and 5–8 of the
Aztpodien regimen, but was given on days 1, 3 and 5 with IL-2 for
8 weeks in the Ravaud trial. Aztpodien gave bolus 5-FU once
weekly in weeks 5–8, while Ravaud gave an infusion of 5-FU for 5
days every 4 weeks, starting in week 1. On the other hand,
Ellerhorst et al (1997) and Tourani et al (1998) use drug schedules
which are quite different again but achieve better response rates
than Ravaud. Thus, the scheduling of these drugs (including doses,
sequencing, drug combination and modes of administration) is
quite different between regimens and may account in some part for
the reported differences in activity.
The importance of patient characteristics is demonstrated by
several studies that have identified a number of factors which have
an impact on the survival of patients with metastatic renal cell
cancer following treatment with IFN-α , IL-2 and chemotherapy
(Elson et al, 1988; Palmer et al, 1992; Jones et al, 1993; Fossa et al,
1995). These prognostic factors are ECOG performance status,
time from diagnosis to treatment and the number of metastatic
sites (Table 3). Joffe et al (1996) reported lower response rates
(17%) to IFN-α –IL-2–5FU (bolus) than Atzpodien and colleagues
(48.6%) but the former study included a high proportion of
moderate (27%) and poor (56%) prognosis patients. Another
example is the recent randomized trial comparing IFN-α –IL-
2–5FU (bolus) with single-agent tamoxifen (Atzpodien et al,
1997), which reported that the median survival of the patients
treated in the tamoxifen arm was 14 months. This is considerably
better than the median survival reported for IFN-α -treated patients
in the randomized MRC trial of IFN-α vs medroxyprogesterone
(8.5 months vs 6 months (Medical Research Council Renal Cancer
Collaborators, 1999)). These data suggest that the clinical charac-
teristics of patients in a study may have a profound effect on the
results. The high response rate reported here is of particular
interest because we have demonstrated that our regimen is active
in poor-prognosis patients and three of these patients have
obtained durable CRs. Furthermore, the median survival of poor-
prognosis patients in our series is similar to those with good 
prognostic features. We have described above how Atzpodien and
colleagues mainly treated good-prognosis patients and demon-
strated high response rates, while Joffe failed to confirm this
activity in a population of poorer-prognosis patients. Our results
confirm those of Atzpodien but in a similar patient population to
those treated by Joffe and colleagues. A possible explanation for
this is our use of PVI 5FU, as opposed to its bolus administration.
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Table 5 Response and survival in evaluable patients
Prognostic group
Good Moderate Poor Overall
(n = 10) (n = 19) (n = 13) (n = 42)
Response rate 20% 42% 54% 40%
Median duration 6 21 NR 73
of response
(weeks)
Median survival 51 87 79 79
(weeks)
1-year survival 51% 62% 64% 60%
NR = not reached
Table 6 Clinical features of complete responders
Disease sites Prognosis Response
group duration
Patient 20 Lung Poor 80+ weeks
Lymph nodes
Patient 21 Lung Poor 98+ weeks
Patient 45 Lung Poor 59+ weeks
Lymph nodes
Table 7 IFN-α –IL-2–5FU studies
First author, Response-rate Median Prognostic Atzpodien
year n survival features regimen
Allen, 2000 55 31% 10.7 mths Poor Yes
Atzpodien, 1993 35 49% N/A Good Yes
Atzpodien, 1997 41 39% 42 mths Good Yes
Hofmockel, 1996 34 38% N/A N/A Yes
Ellerhorst, 1997 55 31% 23 mths Moderate No
Tourani, 1998 62 19% 33% at 2 yrs Moderate No
Dutcher, 1996 36 19% N/A Moderate Yes
Joffe, 1996 55 17% 12 mths Poor Yes
Negrier, 1997 61 8% N/A N/A No
Ravaud, 1998 111 2% 12 mths Poor No
aRandomized; mths = months; N/A = not available5FU, an anti-metabolite, is active principally in the S-phase of the
cell cycle and therefore may be more effective when given as a
protracted venous infusion rather than as a bolus injection, by
increasing the proportion of tumour cells in S-phase which are
exposed to 5FU. This may be particularly important for tumours
with a relatively slow doubling time. In addition, PVI 5FU enables
higher dose-intensity of the drug than intravenous bolus adminis-
tration. PVI 5FU-containing regimens have been associated with
high response rates in breast cancer (Smith et al, 1995) and
relapsed ovarian cancer (Ahmed et al, 1996), improved response
rates and survival in colorectal cancer (Lokich et al, 1989; Meta-
analysis Group in Cancer, 1998) and a survival advantage over a
standard 5FU-containing regimen in oesophagogastric cancer
(Webb et al, 1997).
The IFN-α –IL-2–PVI 5FU regimen that we describe here is
associated with significant toxicity with 36% of patients experi-
encing grade 3 or 4 toxicity, but most episodes were manageable
with appropriate supportive measures. Interestingly, in our study
12 patients (22%) discontinued treatment before completing their
first cycle because of unacceptable toxicity. Half of these patients
were among the first 15 treated, suggesting that with experience
we became better at managing the toxicities associated with this
regimen and identifying those individuals who would be more
likely to tolerate treatment.
From our results and a review of the other phase II studies
combining IFN-α –IL-2–5FU, it is clear that, although there is an
element of empiricism in the cytokine schedule, when this is
altered response rates appear to fall dramatically (Table 7). The
regimen can be associated with significant toxicity in many
patients but the side-effects are manageable in the majority. We
would make the following recommendations concerning further
studies involving IFN-α –IL-2–5FU: randomization against stan-
dard therapy (IFN-α or IL-2 as single agents); inclusion of fit
patients with poor prognostic features; the administration of 5FU
in a prolonged schedule (PVI 5FU or one of the new oral prepara-
tions) should be further explored. In the future, maintenance
cytokine schedules need to be developed.
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